Alan Beckman

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints

R. Meier, D. Blöch, C. Cotrutz et al. · International Journal of Radiation Oncology*Biology*Physics · 2018 · 123 citations · Full text

Use of 10% sulfuric acid/dioxane for removal of <i>N</i>‐α‐tertiary‐butyloxycarbonyl group during solid phase peptide synthesis

Richard A. Houghten, Alan Beckman, John M. Ostresh · International journal of peptide & protein research · 1986 · 40 citations

Several Peptides, Engineering, Biochemistry +15

Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy

Molly Purser, Deirdre Mladsi, Alan Beckman et al. · Advances in Therapy · 2018 · 26 citations · Full text

Five-Year Outcomes From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer

R. Meier, Alan Beckman, G. Henning et al. · International Journal of Radiation Oncology*Biology*Physics · 2016 · 15 citations

Urology, Radiation Medicine, Five-year Outcomes +8

Stereotactic Body Radiation Therapy for Intermediate-risk Organ-confined Prostate Cancer: Interim Toxicity and Quality of Life Outcomes From a Multi-institutional Study

R. Meier, Irving Kaplan, Alan Beckman et al. · International Journal of Radiation Oncology*Biology*Physics · 2012 · 12 citations

Surgical Oncology, Radiation Medicine, Urology +9